GERON CORP Increase (Decrease) in Accounts Receivable
GERON CORP (GERN) reported Increase (Decrease) in Accounts Receivable of $13.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- GERON CORP increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $8.94M, a 67.60% increase year-over-year.
- GERON CORP increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $4.89M.
- GERON CORP increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $1.58M, a 79.45% decline year-over-year.
- GERON CORP increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$1.27M, a 104.69% decline year-over-year.
- GERON CORP increase (decrease) in accounts receivable for fiscal 2025 was $991.00K, a 97.22% decline from fiscal 2024.
- GERON CORP increase (decrease) in accounts receivable for fiscal 2024 was $35.70M.
- GERON CORP increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $13.83M 10-Q · filed 2026-08-05 | $15.41M derived: sum of 3 quarters · filed 2026-08-05 | $14.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.89M 10-Q · filed 2026-05-06 | $6.47M derived: sum of 2 quarters · filed 2026-05-06 | $5.20M derived: sum of 3 quarters · filed 2026-05-06 | $10.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $307.00K derived: sum of 2 quarters · filed 2026-03-02 | $5.64M derived: sum of 3 quarters · filed 2026-08-05 | $991.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | -$1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $4.06M derived: sum of 2 quarters · filed 2026-08-05 | -$589.00K 10-Q · filed 2025-11-07 | $7.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $5.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $684.00K 10-Q · filed 2026-08-05 | $8.37M derived: sum of 3 quarters · filed 2026-08-05 | $35.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$4.65M 10-Q · filed 2026-05-06 | $3.04M derived: sum of 2 quarters · filed 2026-05-06 | $30.17M derived: sum of 3 quarters · filed 2026-05-06 | $31.05M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $34.82M derived: sum of 2 quarters · filed 2026-03-02 | $35.70M derived: sum of 3 quarters · filed 2026-03-02 | $35.70M 10-K · filed 2026-03-02 |
| 2024-09-30 | $27.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $28.01M derived: sum of 2 quarters · filed 2025-11-07 | $28.01M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $874.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $874.00K 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |